Helicon's IPL455,903 found safe; Inflazyme may exercise option

By Angela McDaniels

Seattle, Nov. 23 - Inflazyme Pharmaceuticals Ltd. said preliminary clinical results indicate that IPL455,903, also known as HT-0712, was safe and well tolerated in all volunteers at all doses tested.

The oral, placebo-controlled phase 1b study evaluated doses of up to 135 mg per subject per day for 14 days in healthy adult subjects and was conducted by Inflazyme partner Helicon Therapeutics Inc.

Helicon expects to begin phase 2a testing of the drug as a treatment for memory disorders early next year.

Inflazyme has an option to participate in the development and commercialization of IPL455,903 in learning and memory disorders and has until 90 days after completion of the first phase 2a study to exercise it.

Inflazyme would pay 50% of clinical development costs incurred to the date of exercise and would participate financially in the development and commercialization of the product on an equal basis with Helicon.

If Inflazyme chooses not to exercise the option, it will receive certain royalties on net sales on any product commercialized, the company said.

It is estimated that 14 million people in the United States over 65 years of age are affected by age-associated memory impairment, 4 million of which suffer from mild cognitive impairment. There are no approved pharmaceutical therapeutics to treat these diseases, the company said.

Helicon is a development-phase pharmaceutical company based in New York that develops therapeutics for memory disorders.

Inflazyme is a biopharmaceutical company based in Vancouver, B.C., that develops products for the treatment of patients with respiratory and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.